Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has provided updates on its Phase IIa feasibility trial for ONP-002, a potential treatment for mild traumatic brain injury (mTBI), alongside its U.S. regulatory pathway and NYSE American continued listing status. The company has dosed nine participants across three active Australian clinical sites — Alfred Health, Mackay, and Royal Adelaide Hospital — and has received responses from the U.S. Food and Drug Administration (FDA) related to its Type B meeting request briefing package submitted in July 2026. Oragenics is currently reviewing the FDA responses and remains focused on submitting an Investigational New Drug (IND) application by the end of 2026.
The announcement comes as Oragenics also reported receiving a deficiency letter from NYSE American on Aug. 26, 2026, regarding stockholders’ equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance and intends to do so within the required timeframe. If accepted, the plan would allow Oragenics to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of Feb. 25, 2028.
The dual update underscores the company’s progress in advancing its lead candidate, ONP-002, which is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics’ proprietary intranasal delivery platform is designed to target the brain directly, and the company is exploring its applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
The clinical progress is significant because mTBI, commonly known as concussion, affects millions of people worldwide each year, yet there are currently no FDA-approved treatments specifically for this condition. If ONP-002 proves successful in clinical trials, it could address a major unmet medical need. The ongoing Phase IIa trial in Australia is a critical step, with U.S. Phase 2b trials planned to follow.
However, the NYSE American deficiency letter highlights the financial challenges facing the company. Maintaining its listing on the exchange is crucial for Oragenics to continue accessing public capital markets, which are essential for funding its clinical development programs. The company’s plan to regain compliance will be closely watched by investors, as any failure to meet the exchange’s requirements could result in delisting, which would have significant implications for the company’s ability to raise funds and for its stock’s liquidity.
For more details on the full press release, visit https://nnw.fm/HZ5fb. Information about Oragenics is available at oragenics.com, and the latest news and updates relating to OGEN are available in the company’s newsroom at https://nnw.fm/OGEN.
The company’s ability to navigate both clinical and regulatory hurdles will be key to its future. As Oragenics works to address the NYSE American compliance issue, it continues to make strides in its clinical programs, aiming to bring a much-needed therapy to patients suffering from concussions and other neurological conditions.
